According to reports, a new blood thinner, known as the oral anticoagulant, is said to offer stroke patients, an effective and favorable result.

Stroke in the brain which is connected to blood clot in the heart has been a major source of worry for patients with an irregular heartbeat referred to as a trial fibrillation.

Also, patients who have a high risk of having the condition, generally needed to use a blood thinner, which is said to have an increased rate of side effects.

However, the Philippine Food and Drug Administration is reported to have approved dabigatran etexilate, Boehringer Ingelheim’s new anti-blood clot agent, which prevents stroke, and reduces clogged artery-related deaths in patients with atrial fibrillation.

The drug is currently available to a large number of patients, and its approved recommended daily intake is 150mg twice daily, as for patients that are 75-years-old or have experienced gastro-intestinal bleeding, they get less daily intake of 110mg.

Moreover, the approval was said to be based on discoveries from the Randomized Evaluation of Long-term anticoagulant therapy, which is the largest AF trial completed to date and it is targeted at providing a breakthrough for stroke prevention in AF.